Shin Nippon Biomedical Laboratories Ltd (SNBL) is a provider of drug development services and clinical trials for pharmaceutical companies. The company’s preclinical business offers services such as conducting preclinical studies for the development of pharmaceuticals, medical devices, and regenerative medicines. Its clinical business is a joint venture between Pharmacy Product Development, a contract research organization (CRO), and the company’s clinical division, which provides services for clinical trials ranging from Phase I to Phase IV. SNBL’s translational research business helps bridge basic research and clinical research. The company, in collaboration with the Medipolis Proton Therapy and Research Center, offers integrated and holistic health promotion services and other services to improve coexistence with nature and the realisation of a sustainable society. It also provides in-house developed systems sales/implementation support. SNBL carries out joint research with universities, including safety research on regenerative medicine for Parkinson’s disease using induced pluripotent stem (iPS) cells with Kyoto University’s iPS Cell Research Institute and cancer immunology research with the Center for Advanced Medical Innovation of Kyushu University.
You have successfully subscribed and will receive the next available issues